ACRS
Aclaris Therapeutics Inc
5.20$
-4.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 56.4% | 65.3% | 77.8% | 73.0% | 72.6% | 57.2% | 54.9% | 55.1% | 57.3% | 94.3% | 55.5% | 54.4% | |
| 17.9% | 20.2% | 20.6% | 14.2% | 26.1% | 11.2% | 15.3% | 13.4% | 14.4% | 12.4% | 14.4% | 10.7% | |
| 47.2% | 60.3% | 73.6% | 69.0% | 70.0% | 51.6% | 53.2% | 52.8% | 54.6% | 56.6% | 53.0% | 51.0% | |
| 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 2.7% | 3.5% | 2.4% | 3.5% | |
| -38.4% | – | 0.0% | – | – | – | – | – | – | – | – | – | |
| 2.0% | – | – | – | – | – | – | – | – | – | – | – | |
| 3.2% | 0.1% | – | – | – | – | – | – | – | – | – | – | |
| 28.4% | 20.4% | 18.4% | 16.9% | 28.6% | 29.4% | 27.3% | 30.4% | 31.6% | 35.8% | 27.7% | 30.7% | |
| 12.5% | 15.7% | 11.5% | 9.7% | 10.3% | 14.3% | 10.9% | 14.2% | 14.6% | 17.9% | 13.8% | 15.7% | |
| 0.1% | 0.2% | 0.3% | 0.3% | 0.3% | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | – | |
| 4.4% | 4.5% | 6.2% | 4.5% | 4.2% | 2.1% | 3.2% | 4.7% | 5.2% | 8.2% | 7.4% | 8.6% | |
| 71.6% | 79.6% | 81.6% | 83.1% | 71.4% | 70.6% | 72.7% | 69.6% | 68.4% | 64.2% | 72.3% | 69.3% | |
| -352.3% | -390.5% | -452.6% | -495.9% | -442.1% | -409.8% | -463.4% | -493.5% | -540.1% | -603.1% | -497.0% | -561.6% | |
| 32.4% | 35.9% | 40.8% | 44.3% | 39.1% | 43.3% | 61.8% | 64.8% | 69.9% | 76.4% | 64.8% | 79.4% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.